Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan
affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with
essential hypertension (EH).